Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Profound Medical Corp. (NASDAQ:PROF) will release its first quarter 2023 financial results after the market closes on May 10, 2023. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will review the financial outcomes and discuss recent business developments. Profound is known for its incision-free therapies for the ablation of diseased tissue, notably its TULSA-PRO® technology, which offers customizable, radiation-free treatments for prostate issues. The company has also commercialized Sonalleve®, a platform for treating uterine fibroids and palliative pain in bone metastases, which holds multiple regulatory approvals including FDA clearance.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will present an update on its business at the Bloom Burton & Co. Healthcare Investor Conference on April 26, 2023, at 10:00 a.m. Eastern Time, held at the Metro Toronto Convention Centre. The presentation will be accessible via live broadcast and archived on the Company's website under the Investors section.
Profound specializes in incision-free therapies for ablation of diseased tissue, including their advanced TULSA-PRO® technology, which combines MRI imaging with focused ultrasound for customizable prostate treatments. TULSA-PRO® is FDA cleared and CE marked. The Company also offers Sonalleve®, a platform for treating uterine fibroids and palliative treatments for bone metastases, which holds various international approvals. For more details, visit www.profoundmedical.com.
Profound Medical Corp. (NASDAQ: PROF) reported its financial results for Q4 and the full year 2022. Q4 revenue reached approximately $1.3 million, a 26% increase from the prior year, driven entirely by recurring revenue from TULSA-PRO® consumables and related services. Operating expenses decreased by 8% to $9.4 million. The net loss for Q4 was $9.5 million, or $0.46 per share. For the full year, total revenue was approximately $6.7 million, down slightly from $6.9 million in 2021, with a notable decline in one-time capital sales due to COVID-19 challenges. The company maintains a cash balance of $46.5 million as of December 31, 2022.
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) announced that CEO Arun Menawat will present a business update at the 43rd Annual Cowen Health Care Conference on March 8, 2023, at 9:10 a.m. ET. The presentation will be live-streamed and archived on the Company’s website under the Investors section.
Profound specializes in customizable, incision-free therapies for diseased tissue ablation. Its flagship products include TULSA-PRO®, designed for precise prostate ablation, and Sonalleve®, used for treating uterine fibroids and palliative pain. Both technologies have received multiple regulatory approvals.
Profound Medical Corp. (NASDAQ:PROF) announced it will release its fourth quarter and full year 2022 financial results on March 7, 2023, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results and business developments. Profound specializes in customizable, incision-free therapies for tissue ablation, notably through its products TULSA-PRO and Sonalleve. Both technologies hold various medical approvals, enhancing the company’s market footprint. Investors can access the live call through a registration link provided in the announcement.